Clinical data | |
---|---|
Other names | AD-85481, ALN-85481, ALN-AGT01 |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
UNII |
Zilebesiran is an experimental small interfering RNA developed by Roche and Alnylam that is administered subcutaneously twice annually to lower blood pressure in people already taking other antihypertensive drugs.[1][2][3] It works by impeding the synthesis of angiotensinogen in the liver.[4][5]